News

June 28, 2019June 28, 2019

PARP Inhibitors Used in ‘One-two Punch’ Strategy to Kill OC Cells in Mouse Models, Study Shows

News

Researchers have developed a two-step approach that harnesses the aging process of cells, allowing breast and ovarian cancers to be effectively targeted and destroyed in cell and mouse preclinical models. ... Read more

June 26, 2019

FDA Grants Priority Review to GSK’s Zejula for Late Stage Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has accepted the application of Tesaro, a GSK company, seeking to extend approval for Zejula (niraparib) to women with late stage ovarian cancer ... Read more

June 24, 2019

Researchers Work to Create Screening Tool for Early or Pre-cancerous OC

News

Researchers from Clemson University and doctors from South Carolina’s Prisma Health-Upstate are collaborating to develop a screening tool that can identify ovarian cancer in its earlier stages, or even before ... Read more

June 19, 2019

Lynparza Approved in Europe as Initial Maintenance Therapy for Some OC

News

Women in the European Union with BRCA-mutated advanced ovarian cancer can now receive Lynparza (olaparib) as a first-line maintenance treatment, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) ... Read more

June 17, 2019

Sentinel Node Biopsy Feasible to Determine Spread of Early-stage OC

News

A sentinel node biopsy, used to determine whether cancer has spread to lymph nodes, is a feasible way to obtain information and avoid lymph node dissection in patients with early-stage ... Read more

June 14, 2019June 14, 2019

First Patient Dosed in Phase 2 Trial Evaluating Ampligen-Keytruda-Chemo Combo for Ovarian Cancer

News

The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is ... Read more

June 13, 2019June 21, 2019

Groups to Jointly Invest $8 Million in Ovarian Cancer Research Projects

News

To help find innovative ways to detect, treat, and prevent ovarian cancer, the Ovarian Cancer Research Alliance and the American Cancer Society plan to jointly invest $8 million in four ... Read more

June 12, 2019

Rubraca Maintenance Delays Disease Progression in Subsequent Treatments for Recurrent OC, Phase 3 Trial Shows

News

Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent ... Read more

June 7, 2019

Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports

News

The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to ... Read more

June 5, 2019June 5, 2019

Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows

News

Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival ... Read more